ProTransit Nanotherapy

Executive Summary

ProTransit Nanotherapy is a private US biotechnology company advancing Pro-MP™, a patented sustained-release microparticle platform designed to penetrate skin, scalp, eye, and mucosal tissues for localized drug delivery. The platform aims to improve efficacy and safety over traditional oral or injectable routes by enabling prolonged, controlled release of active ingredients. Initial applications target dermatology and hair regrowth, addressing large markets with high unmet need for non-invasive, long-acting therapies. Founded in 2016 and based in Houston, Texas, the company is in early development stages with no disclosed funding or clinical data yet. Its technology could potentially extend to ophthalmic, topical, and mucosal indications, offering a versatile alternative to existing delivery methods. Near-term progress depends on securing partnerships or completing preclinical studies to demonstrate proof-of-concept in humans.

Upcoming Catalysts (preview)

• Q3 2026Release of preclinical data for hair regrowth formulation40% success
• Q2 2026Strategic partnership with dermatology or cosmetic company30% success
• Q4 2026FDA pre-IND meeting or orphan drug designation for a lead candidate25% success